

Table 1. Comparison of baseline characteristics between patients with and without recurrence

	Total n = 190	Recurrence group n = 21	Non-Recurrence group n = 169	P-value
Age (years)	65 ± 11	67 ± 12	65 ± 11	0.38
Female, n (%)	71 (37.4)	11 (52.4)	60 (35.5)	0.13
BMI (kg/m <sup>2</sup> )	23.8 ± 3.5	24.4 ± 3.7	23.8 ± 3.5	0.43
<b>Echocardiographic parameters</b>				
LAD (mm)	37.7 ± 5.3	38.1 ± 5.1	37.6 ± 5.3	0.72
LVEF (%)	67.8 ± 6.2	69.2 ± 4.0	67.6 ± 6.5	0.28
<b>Electrocardiographic parameters</b>				
P-wave duration in lead II (ms)	121.8 ± 19.4	119.2 ± 19.6	122.1 ± 19.3	0.54
P-wave duration in lead V <sub>1</sub> (ms)	106.2 ± 18.0	108.8 ± 13.3	105.9 ± 18.5	0.49
QRS complex duration in lead II (ms)	89.1 ± 16.8	85.8 ± 15.3	89.4 ± 17.0	0.35
QRS complex duration in lead V <sub>1</sub> (ms)	101.0 ± 16.1	98.0 ± 19.6	101.4 ± 15.7	0.37
QTc interval (ms)	419.0 ± 22.5	417.4 ± 23.5	419.4 ± 22.3	0.74
<b>Laboratory parameters</b>				
BNP level (pg/mL)	48.9 [22.9-96.7]	79.2 [30.8-183.7]	45.2 [22.3-85.4]	0.45
CCr (mL/min)	64.2 [53.1-77.9]	67.2 [49.3-80.7]	64.9 [53.3-77.8]	0.65
<b>Underlying disease, n (%)</b>				
Heart failure	10 (5.3)	1 (4.8)	9 (5.3)	0.91
Hypertension	98 (51.9)	11 (55.0)	87 (51.5)	0.77
Diabetes mellitus	19 (10.0)	2 (9.5)	17 (10.6)	0.94
Stroke	10 (5.3)	1 (4.8)	9 (5.4)	0.91
<b>CHADS<sub>2</sub> score (points)</b>	1 [0-2]	1 [0-2]	1 [0-2]	0.51
<b>Procedure, n (%)</b>				
PVI alone	159 (83.7)	15 (71.4)	144 (85.2)	0.11
PVI + other procedures	31 (16.3)	6 (28.6)	25 (14.8)	
<b>Medication, n (%)</b>				
β-blocker	65 (34.2)	10 (47.6)	55 (32.5)	0.17
RASI	71 (37.6)	6 (28.6)	65 (38.7)	0.37
MRA	7 (3.7)	1 (4.8)	6 (3.6)	0.78
Statin	49 (25.8)	5 (23.8)	44 (26.0)	0.83

Table1. Comparison of baseline characteristics between patients with and without recurrence

Values are presented as mean ± standard deviation, median with interquartile range, or n (%).

BMI: Body mass index, LAD: Left atrium diameter, LVEF: left ventricular ejection fraction, BNP: B-type natriuretic peptide, CCr: Creatinine clearance, PVT: Pulmonary vein isolation, RASi: Renin-angiotensin system inhibitor, MRA: Mineralocorticoid receptor antagonist